Simple Search Results

Query String: PACLITAXEL

taxol CHEMBL428647 BDBM50001839 PACLITAXEL

Dong, Y; Wang, S; Wang, C; Li, Z; Ma, Y; Liu, G Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis. J Med Chem 60: 1219-1224 (2017)
Machulkin, AE; Skvortsov, DA; Ivanenkov, YA; Ber, AP; Kavalchuk, MV; Aladinskaya, AV; Uspenskaya, AA; Shafikov, RR; Plotnikova, EA; Yakubovskaya, RI; Nimenko, EA; Zyk, NU; Beloglazkina, EK; Zyk, NV; Koteliansky, VE; Majouga, AG Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. Bioorg Med Chem Lett 29: 2229-2235 (2019)
Chen, YF; Wu, CH; Chen, LH; Lee, HW; Lee, JC; Yeh, TK; Chang, JY; Chou, MC; Wu, HL; Lai, YP; Song, JS; Yeh, KC; Chen, CT; Lee, CJ; Shia, KS; Shen, MR Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy. J Med Chem 65: 4767-4782 (2022)
Lis, LG; Smart, MA; Luchniak, A; Gupta, ML; Gurvich, VJ Synthesis and Biological Evaluation of a Biotinylated Paclitaxel With an Extra-Long Chain Spacer Arm. ACS Med Chem Lett 3: 745-748 (2012)
Ayoub, AT; Abou El-Magd, RM; Xiao, J; Lewis, CW; Tilli, TM; Arakawa, K; Nindita, Y; Chan, G; Sun, L; Glover, M; Klobukowski, M; Tuszynski, J Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism. J Med Chem 59: 9532-9540 (2016)
Iwaki, Y; Ohhata, A; Nakatani, S; Hisaichi, K; Okabe, Y; Hiramatsu, A; Watanabe, T; Yamamoto, S; Nishiyama, T; Kobayashi, J; Hirooka, Y; Moriguchi, H; Maeda, T; Katoh, M; Komichi, Y; Ota, H; Matsumura, N; Okada, M; Sugiyama, T; Saga, H; Imagawa, A ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. ACS Med Chem Lett 11: 1335-1341 (2020)
Dadgar, S; Ramjan, Z; Floriano, WB Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A. J Med Chem 56: 2791-803 (2013)
Chen, X; Plasencia, C; Hou, Y; Neamati, N Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 48: 1098-106 (2005)
Poh Yen, K; Stanslas, J; Zhang, T; Li, H; Wang, X; Kok Meng, C; Kok Wai, L Synthesis of small molecules targeting paclitaxel-induced MyD88 expression in triple-negative breast cancer cell lines. Bioorg Med Chem 49: (2021)
Guo, XM; Yadav, MB; Khan, M; Hao, CW; Lin, CY; Huang, T; Wu, J; Fan, BM; Bian, ZX Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer. J Med Chem 64: 17051-17062 (2021)
Kawahara, B; Faull, KF; Janzen, C; Mascharak, PK Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. J Med Chem 64: 8437-8446 (2021)
Shi, W; Zhang, P; Zou, F; Zhou, J; Yin, Z; Cai, Z; Ghaleb, H; Jiang, Y; Huang, W; Liu, Y; Qiu, Q; Qian, H Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel. Eur J Med Chem 233: (2022)
Kimura, Y; Aoki, J; Kohno, M; Ooka, H; Tsuruo, T; Nakanishi, O P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 49: 322-8 (2002)
Colombo, R; Mingozzi, M; Belvisi, L; Arosio, D; Piarulli, U; Carenini, N; Perego, P; Zaffaroni, N; De Cesare, M; Castiglioni, V; Scanziani, E; Gennari, C Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3. J Med Chem 55: 10460-74 (2012)
Wang, S; Yang, J; Li, X; Liu, Z; Wu, Y; Si, G; Tao, Y; Zhao, N; Hu, X; Ma, Y; Liu, G Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo. J Med Chem 60: 5162-5192 (2017)